ObsEva SA: ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the